Document is current

Article History

Received: 6 June 2021

Accepted: 16 August 2021

First Online: 24 August 2021

Declarations

:

: Dr. Sunakawa reports grants and personal fees from Taiho Pharmaceutical, Chugai Pharma, Takeda, Eli Lilly Japan, and Sanofi; personal fees from Bayer Yakuhin, Yakult Honsha, Bristol-Myers Squibb Japan, Merck Biopharma, Ono Pharma, MSD, Daiichi Sankyo; and grants from Otsuka. Dr. Inoue reports personal fees from Bristol-Myers Squibb Japan, Pfizer, Nippontect systems, and RCR. Dr. Kito reports personal fees from Taiho Pharmaceutical, Chugai Pharma, Merck Biopharma, and Takeda. Dr. Takahashi reports personal fees from Takeda. Dr. Makiyama reports personal fees from Eli Lilly Japan, Taiho Pharmaceutical, Ono Pharma, Bristol-Myers Squibb Japan, and Daiichi Sankyo. Dr. Yasui reports personal fees from Daiichi Sankyo, Ono Pharma, Taiho Pharmaceutical, Bristol-Myers Squibb Japan, Chugai Pharma, Takeda, Eli Lilly Japan, TERUMO, Merck Biopharma, Yakult Honsha, and Bayer Yakuhin. Dr. Matoba reports stock of DNA chip Research Inc.. Dr. Kawakami reports grants and personal fees from Bristol-Myers Squibb Japan; personal fees from Ono Pharm. Dr. Nakajima reports grants from Sumitomo Dainippon Pharma, Boehringer Ingelheim, Bristol-Myers Squibb, Nippon Kayaku, Chugai Pharmaceutical, Sanofi, Taiho Pharmaceutical, Takeda, Eli Lilly Japan, Merck Biopharm, Daiichi Sankyo, Towa Pharmaceutical, Ono Pharm, MSD, Astellas Pharma Inc., Eisai, Solasia Pharma, Parexel International, A2 Healthecare, Mediscience Planning Inc., ICON Japan, EPS Holdings, Inc., and Japan Clinical Research Operations; personal fees from Sumitomo Dainippon Pharma, Boehringer Ingelheim, Bristol-Myers Squibb, Ono Pharm, Taiho Pharmaceutical, Takeda, Amgen Inc., Chugai Pharmaceutical, Sanofi, Novartis Japan, Nippon Kayaku, MSD, Eli Lilly Japan, Bayer Yakuhin, Pfizer, Daiichi Sankyo, Yakult Honsha, Nipro Co, Merck Biopharm, Celltrion Healthcare Japan, Teijin Pharma, and Sawai Pharmaceutical. Dr. Muro reports grants from Solasia Pharma, Merck Biopharm, Daiichi Sankyo, Parexel International, Pfizer, and MSD; grants and personal fees from Amgen, grants and personal fees from Ono Pharm, Sanofi, and Taiho Pharmaceutical; personal fees from AstraZeneca, Chugai Pharmaceutical, Takeda, Eli Lilly Japan, Bristol-Myers Squibb, and Bayer Yakuhin. Dr. Ichikawa reports grants from Takeda, Taiho Pharmaceutical, Chugai Pharmaceutical, Merck Biopharm, Shionogi, and Ono Pharmaceutical; Merck Biopharm, Chugai Pharmaceutical, and Bayer Yakuhin. All remaining authors have declared no conflicts of interest.

Free to read: This content has been made available to all.